In the present study, global proteome profiling of serum and urine revealed that orosomucoid-2 (ORM2), an acute phase reactant, was differentially expressed in rheumatoid arthritis (RA) patients and exhibited the highest fold change. The gene discussed is ORM2; the disease is rheumatoid arthritis.